ADXS - Advaxis Inc

From OTC Wiki
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.


Click the menu options below to view or add content

Opinions

No opinions so far.

Please login or register to post your opinion.

Links

Edit Links page

Company

News

Create News

Mon, 22:40 September 12, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Advaxis, Inc. | Tier: OTCQX U.S. | Source: GLOBE |
Fri, 20:06 June 3, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Advaxis, Inc. | Tier: OTCQX U.S. | Source: GLOBE |
Wed, 14:01 April 27, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Advaxis, Inc. | Tier: OTCQX U.S. | Source: GLOBE |
Fri, 12:01 April 8, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Advaxis, Inc. | Tier: OTCQX U.S. | Source: GLOBE |
Mon, 16:59 March 28, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Advaxis, Inc. | Tier: OTCQX U.S. | Source: BUSI |
Thu, 13:01 March 17, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Advaxis, Inc. | Tier: OTCQX U.S. | Source: GLOBE |

More News: Company News | OTC Markets